We investigated the occurrence of color vision loss in 70 organic solvent mixtures exposed workers and in 47 controls. Color Vision was assessed with a color arrangement test designed to identify the defective color sense, the Han Double 15-Hue Test. The results of the test were no significant difference between exposed workers and controls in the proportion of subjects who committed one or two errors. Quantitative analysis, using color confusion index(CCI), showed no signifiant difference between exposed workers and controls. A significant linear correlation was present between age and CCI in both exposed workers(CCi=0.0056age + 0.94; r=0.23; p<0.05) and controls(CCI=0.0066age + 0.86; r=0.33; p<0.05). Qualitative analysis of the patterns on the hue circle showed that the prevalence of acquired dyschromatopsia was 21% in both and no significant difference. Multiple regression analyses showed that age was significantly related to color vision loss. These results did not provide evidence of a relationship between organic solvents exposure and incidence of color vision loss. In field studies for monitor the people at risk of the acquired color vision loss involving low-dose organic solvents exposed workers, both quantitative and qualitative information should be considered.
Color Vision ; Incidence ; Prevalence ; Solvents

Acrodermatitis enteropathica(AE) which starts in early infancy after weaning is a rare hereditary chronic disorder of zinc absorption. AE is characterized by alopecia, diarrhea and skin lesions localized to periorificial areas and acrally on the extremities. However, recent reports presented Transient Symptomatic Zinc Deficiency(TSZD) in preterm infants. TSZD is clinically similar to AE and skin lesions rapidly heals after zinc supplementation. When the treatment was withheld, no recurrence was seen. We experienced a TSZD case in a cow's milk fed, preterm infant, so We report it with a brief review of literature.
Absorption ; Acrodermatitis ; Alopecia ; Diarrhea ; Extremities ; Humans ; Infant* ; Infant, Newborn ; Infant, Premature* ; Milk* ; Recurrence ; Skin ; Weaning ; Zinc*

No abstract available.
Arthritis, Juvenile*

The muscle glycogen is an important energy source for muscle contraction especially in prolonged exercise. One of the important factors for improvement of physical performance in athletes is the storage of extra-amount of glycogen (supercompensation) in liver and muscles. During 120 minutes treadmill exercise (intensity of exercise was approximatly 80% VO2max), the glycogen concentration was significantly decreased to 36% in liver and 46% in muscles after 60 minutes exercise. At 90 and 120 minutes of exercise, the level of glycogen concentration of liver and muscles statistically were not different from the levels of the 60 minutes exercise. The repletions of glycogen in the liver and muscles in overnight fasted control(C) and 120 minutes treadmill exercise(E) groups during l80minutes after glucose ingestion were investigatect. ln the liver, the concentration of glycogen in C and E groups were markdly increased till 120 minutes after zlucose ingestion, hut the levels of concentration at 180 minutes were decreased comparing to the levels of 120 minutes in both groups. In the muscles, the repletion of glycogen at 60, 120 and 180 minutes of C and E groups were significantly increased comparing to 0 minute of respective groups in the soleus and plantaris muscles. In soleus(SOL), the repletion of glycogen in all of the E groups was significantly higher than that of the respective C groups. However, the repletion of glycogen in all of the E groups of plantaris was revealed higher tendency comparing to respective C groups. Mean repletion rates of glycogen in liver and muscles after glucose ingestion were highest during the first 60 minutes in all groups and the rates of E groups were 2-3 times than those of respective C groups. These results suggest that the glycogen supercompensation in the muscle be provided with decrement of glycogen concentration by exercise, increment of glucose uptake by muscuiar contraction itself and increased insuJin level, and the activation of glycogen synthetase by insulin.
Animals ; Athletes ; Eating* ; Glucose* ; Glycogen Synthase ; Glycogen* ; Humans ; Insulin ; Liver* ; Muscle Contraction ; Muscles ; Rats*

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder that significantly diminishes the quality of life of patients.Current pharmacological treatments are often limited by low therapeutic efficacy and severe side effects, restricting their long-term application. This necessitates the development of novel therapeutic strategies. Exosome-based therapies have recently emerged as promising candidates due to the therapeutic potential demonstrated by exosomes derived from mammalian cells and plant sources in IBD management. These exosomes exhibit antiinflammatory effects by downregulating proinflammatory cytokine expression, modulating macrophage polarization, and promoting mucosal regeneration. However, scalability challenges and high production costs hinder the clinical translation of mammalian cell-derived exosomes. In contrast, plant-derived exosomes offer distinct advantages, including cost-effective large-scale production, enhanced stability, and reduced immunogenicity, positioning them as a emerging next-generation therapeutic modality for IBD. However, there are still some hurdles in the standardization of largescale exosome production and the precise elucidation of their therapeutic mechanisms. Future research needs to focus on optimizing exosome manufacturing processes, conducting mechanistic studies, and combinatory approaches to accelerate clinical application.

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder that significantly diminishes the quality of life of patients.Current pharmacological treatments are often limited by low therapeutic efficacy and severe side effects, restricting their long-term application. This necessitates the development of novel therapeutic strategies. Exosome-based therapies have recently emerged as promising candidates due to the therapeutic potential demonstrated by exosomes derived from mammalian cells and plant sources in IBD management. These exosomes exhibit antiinflammatory effects by downregulating proinflammatory cytokine expression, modulating macrophage polarization, and promoting mucosal regeneration. However, scalability challenges and high production costs hinder the clinical translation of mammalian cell-derived exosomes. In contrast, plant-derived exosomes offer distinct advantages, including cost-effective large-scale production, enhanced stability, and reduced immunogenicity, positioning them as a emerging next-generation therapeutic modality for IBD. However, there are still some hurdles in the standardization of largescale exosome production and the precise elucidation of their therapeutic mechanisms. Future research needs to focus on optimizing exosome manufacturing processes, conducting mechanistic studies, and combinatory approaches to accelerate clinical application.

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder that significantly diminishes the quality of life of patients.Current pharmacological treatments are often limited by low therapeutic efficacy and severe side effects, restricting their long-term application. This necessitates the development of novel therapeutic strategies. Exosome-based therapies have recently emerged as promising candidates due to the therapeutic potential demonstrated by exosomes derived from mammalian cells and plant sources in IBD management. These exosomes exhibit antiinflammatory effects by downregulating proinflammatory cytokine expression, modulating macrophage polarization, and promoting mucosal regeneration. However, scalability challenges and high production costs hinder the clinical translation of mammalian cell-derived exosomes. In contrast, plant-derived exosomes offer distinct advantages, including cost-effective large-scale production, enhanced stability, and reduced immunogenicity, positioning them as a emerging next-generation therapeutic modality for IBD. However, there are still some hurdles in the standardization of largescale exosome production and the precise elucidation of their therapeutic mechanisms. Future research needs to focus on optimizing exosome manufacturing processes, conducting mechanistic studies, and combinatory approaches to accelerate clinical application.

No abstract available.

The present study was aimed at investigating the role of type II 11beta-hydroxysteroid dehydrogenase (IIbeta- HSD II) in the development of hypertension. Two-kidney, one-clip (2K1C), deoxycorticosterone acetate (DOCA)/salt, or NG-nitro-L-arginine methyl ester (L-NAME) hypertension was induced in male Sprague- Dawley rats. Four weeks later, the expression of 11beta-HSD II mRNA was determined in the kidney by Northern blot analysis. The plasma level of aldosterone was measured by radioimmunoassay. In 2K1C hypertension, the expression of 11beta-HSD II was decreased in the clipped kidney and increased in the non-clipped kidney. The expression was increased in the remnant kidney of DOCA/salt hypertension, while decreased in the kidneys of L-NAME hypertension. The plasma level of aldosterone was increased, decreased, and remained unchanged in 2K1C, DOCA/salt, and L-NAME hypertension, respectively. The down-regulation of 11beta-HSD II may contribute to the sodium retention, thereby increasing the blood pressure in 2K1C and L-NAME hypertension. On the contrary, the up-regulation in DOCA/salt hypertension may play a compensatory role to dissipate the sodium retention.
11-beta-Hydroxysteroid Dehydrogenases* ; Aldosterone ; Animals ; Blood Pressure ; Blotting, Northern ; Desoxycorticosterone ; Down-Regulation ; Humans ; Hypertension* ; Kidney* ; Male ; NG-Nitroarginine Methyl Ester ; Plasma ; Radioimmunoassay ; Rats* ; RNA, Messenger ; Sodium ; Up-Regulation

PURPOSE: TRAM flap reconstruction has settled down as a common method for breast reconstruction after mastectomy. There are a few surgical contraindication in TRAM flap surgery. Previous abdominal liposuction has been a relative contraindication in TRAM flap surgery. The authors present 2 patients of successful breast reconstruction using pedicled TRAM flaps, who previously underwent abdominal liposuction. METHODS: Case 1: A 48-year-old woman with a right breast cancer visited for mastectomy and breast reconstruction. Her past surgical history was notable for abdominal liposuction 15 years ago. Skin sparing mastectomy and breast reconstruction with a pedicled TRAM flap was performed. Case 2: A 45-year-old woman with a left breast cancer visited us for mastectomy and autologous breast reconstruction. 3 years ago, she had an abdominal liposuction and augmentation mammaplasty in other hospital. Nipple sparing mastectomy and breast reconstruction was done using pedicled TRAM flap. RESULTS: One year after the reconstruction, partial fat necrosis was developed in one case but there was no skin necrosis or donor site complication in both patients. CONCLUSION: As aesthetic surgery becomes more popular, increasing numbers of patients who have a prior abdominal liposuction history want for autologous tissue breast reconstruction. In these patients, TRAM flap surgery will be also used for breast reconstruction. But, the warning of fat necrosis and the use of preoperative Doppler tracing to evaluate the abdominal perforator may be beneficial to patients who had abdominal liposuction recently.
Breast ; Breast Neoplasms ; Fat Necrosis ; Female ; Humans ; Lipectomy ; Mammaplasty ; Mastectomy ; Middle Aged ; Necrosis ; Nipples ; Skin ; Tissue Donors